Anti-cancer medicines, Filgen

Composition:FILGEN contains filgrastim, [INN: recombinant-methionyl human granulocyte-colony stimulating factor, r-met-HuG-CSF, from E. coli bacteria.

Each 1.0 mL single use vial contains 300 mcg of filgrastim.

Indications:FILGEN is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and for the reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia.

FILGEN is also indicated for the mobilisation of peripheral blood progenitor cells (PBPC).

In patients, children or adults, with severe congenital, cyclic, or idiopathic neutropenia with an ANC of 0.5 x 109/L, and a history of severe or recurrent infections, long term administration of FILGEN is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.

FILGEN is indicated for the treatment of persistent neutropenia (ANC less than or equal to 1.0 x 109/L) in patients with advanced HIV infection, in order to reduce the risk of bacterial infections when other options to manage neutropenia are inappropriate.

Dosage and administration:The recommended dose of FILGEN is 0.5 MU (5 µg)/kg/day. The first dose of FILGEN should not be administered less than 24 hours following cytotoxic chemotherapy.
How supplied:Each 1.0 ml single use vial contains 300 µg (30 million units) of filgrastim.
Storage condition:Store between 2 to 8 degree C.
Shelf life:Shelf life of the medicinal product: 2 years.